Joanne Wallace summarises the recent Cochrane systematic review on risperidone versus placebo for schizophrenia, which concludes that the best available evidence does not show that the benefits of risperidone outweigh the harms.
The post Risperidone versus placebo for people with schizophrenia appeared first on National Elf Service.